Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

United Guardian Q3 2026 Results: Net Income $931K, Up 246.8% YoY

United-Guardian, Inc. reported a significant increase in net income for the third quarter of 2026, rising to $930,912 from $268,441 in the prior year, driven by a 54% increase in net sales. For the first nine months of 2026, net income reached $2,478,393, supported by higher sales and settlement income of $339,493.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue3.52.3
Profit before tax1.20.3
Net income0.90.3
EPS (diluted, $ a share)$0.20$0.06

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+246.8%
Revenue, year on year+54.3%
Operating margin31.7%
Source

10-Q filed with the SEC, NASDAQ: UG. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

United Guardian Inc: key numbers

Share price
$8.08Close, Nov 16
Market cap
$37.1M
Shares outstanding
4.59MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Perfumes, Cosmetics & Other Toilet PreparationsSIC 2844

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from United Guardian Inc

All →
9:01 AM ET 8-K
Financial Results

United Guardian Financial Results

United-Guardian reported strong third quarter 2026 results with net sales increasing 54% to $3.5 million and net income surging 247% to $0.93 million. Growth was driven by a 187% increase in cosmetic ingredient sales and a 29% rise in pharmaceutical sales, specifically for its lead product Renacidin.

Term
Q3 2026

“I am very excited to report that our third quarter was exceptionally strong, with pharmaceuticals, personal care and medical lubricants all posting sales increases. Pharmaceutical sales grew 29% compared with the same period in 2025, driven primarily by Renacidin®, our most important pharmaceutical product.”

Donna Vigilante, President of United-Guardian

“I am very pleased with our performance for the first nine months of 2026. Our growth initiatives have produced encouraging results, and we plan to continue building on this progress.”

Donna Vigilante, President of United-Guardian

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.